



Bundesamt für Verbraucherschutz und Lebensmittelsicherheit (BVL)
Federal Office of Consumer Protection and Food Safety
Mauerstraße 39-42
10117 Berlin
(Germany)

DECENTRALISED PROCEDURE

**PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY
MEDICINAL PRODUCT**

Prednisolon ad us. vet. (AT, DE)
Cortico Veyxin (BE, BG, CY, CZ, EE,
EL, FR, HU, IE, IS, IT, LT, LU, LV, PL,
RO, SI, SK, UK)
Veyxin (DK, ES, PT)
10 mg/ml suspension for injection

Date: 27 September 2018

MODULE 1

PRODUCT SUMMARY

EU Procedure number	DE/V/0162/001/DC
Name, strength and pharmaceutical form	Prednisolon ad us. vet (AT, DE) Cortico Veyxin (BE, BG, CY, CZ, EE, EL, FR, HU, IE, IS, IT, LT, LU, LV, PL, RO, SI, SK, UK) Veyxin (DK, ES, PT) 10 mg/ml suspension for injection
Applicant	Veyx-Pharma GmbH Söhreweg 6 34639 Schwarzenborn Germany
Active substance(s)	Prednisolone acetate
ATC Vetcode	QH02AB06
Target species	Cattle, horse, dog and cat
Indication for use	<u>In horses, cattle, dogs and cats:</u> Supportive treatment of acute non-infectious arthritis, bursitis, tenosynovitis or allergic skin disease. <u>In cattle:</u> Supportive treatment of primary ketosis (acetonæmia).

MODULE 2

The Summary of Product Characteristics (SPC) for this product is available on the Heads of Veterinary Medicinal Agencies website (www.hma.eu).

MODULE 3

PUBLIC ASSESSMENT REPORT

Legal basis of original application	Application in accordance with Article 13 (1) of Directive 2001/82/EC as amended.
Date of completion of the original decentralised procedure	04 July 2018
Date product first authorised in the Reference Member State (MRP only)	Not applicable
Concerned Member States for original procedure	AT, BE, BG, CY, CZ, DK, EE, EL, ES, FR, HU, IE, IS, IT, LT, LU, LV, PL, PT, RO, SI, SK, UK

I. SCIENTIFIC OVERVIEW

The product has been developed as a generic of Prednisolonacetat 1%, suspension for injection for use in cattle, horse, dog and cat. The reference product is marketed by Bela-Pharm GmbH & Co.KG and has been authorised in the DE since November 2005.

The product is produced and controlled using validated methods and tests, which ensure the consistency of the product released on the market.

It has been shown that the product can be safely used in the target species; the slight reactions observed are indicated in the SPC.

The product is safe for the user, the consumer of foodstuffs from treated animals and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC.

The efficacy of the product was demonstrated according to the claims made in the SPC.

The overall risk/benefit analysis is in favour of granting a marketing authorisation.

II. QUALITY ASPECTS

A. Qualitative and quantitative particulars

The product contains 10 mg/ml prednisolone acetate as active substance and the excipients benzyl alcohol, polysorbate 80, colloidal anhydrous silica and water for injection.

The container is a colourless glass type II vial with bromobutyl rubber stopper and aluminum cap.

The choice of the presence of the preservative, benzyl alcohol, is justified.

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

B. Method of Preparation of the Product

The product is manufactured fully in accordance with the principles of good manufacturing practice at a licensed manufacturing site.

Process validation data on the product have been presented in accordance with the relevant European guidelines.

C. Control of Starting Materials

The active substance is Prednisolone acetate, an established substance described in the European Pharmacopoeia. The active substance is manufactured in accordance with the principles of good manufacturing practice.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

Scientific data and certificates of suitability issued by the EDQM have been provided

There are no substances within the scope of the TSE Guideline present or used in the manufacture of this product.

D. Control on intermediate products

The tests performed during production are described and the results of three consecutive runs conform to the specifications.

E. Control Tests on the Finished Product

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product.

Satisfactory validation data for the analytical methods have been provided.

Batch analytical data from the proposed production sites have been provided demonstrating compliance with the specification.

F. Stability

Stability data on the active substance have been provided in accordance with applicable European guidelines, demonstrating the stability of the active substance when stored under the approved conditions.

Stability data on the finished product have been provided in accordance with applicable European guidelines, demonstrating the stability of the product throughout its shelf life when stored under the approved conditions.

The stability of the finished product of 14 days after broaching has been demonstrated.

G. Other Information

Not applicable.

III. SAFETY AND RESIDUES ASSESSMENT (PHARMACO-TOXICOLOGICAL)

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, safety studies are not required.

The pharmacological and toxicological aspects of this product are identical to the reference product.

Warnings and precautions as listed on the product literature are adequate to ensure safety of the product to users and consumers.

Environmental Risk Assessment

A Phase I environmental risk assessment (ERA) was provided according to the CVMP/VICH guidelines.

Phase I:

The product is intended for use in individual animals only, therefore according to the Phase I Decision Tree an adverse environmental impact is not anticipated. A Phase II assessment is not considered to be necessary.

III.B Residues documentation

Residue Studies

No residue depletion studies were conducted as this is a generic application submitted according to Article 13 (1) of Directive 2001/82/EC as amended and bioequivalence with the reference product can be assumed.

The withdrawal period for horse was extrapolated from the withdrawal period for cattle according to the guideline on "Safety and residue data requirements for veterinary medicinal products intended for minor uses or minor species" (EMA/CVMP/SWP/66781/2005).

MRLs

Prednisolon is included in Table 1 of the Annex to Commission Regulation (EU) No 37/2010 as follows:

Pharmacologically active substance	Marker residue	Animal Species	MRL	Target tissues	Other provision	Therapeutic Classification
Prednisolone	Prednisolone	Bovine	4 µg/kg 4 µg/kg 10 µg/kg 10 µg/kg 6 µg/kg	Muscle Fat Liver Kidney Milk	NO ENTRY	Corticoids/ Glucocorticoids
		Equidae	4 µg/kg 8 µg/kg 6 µg/kg 15 µg/kg	Muscle Fat Liver Kidney		

Withdrawal Periods

Based on the data provided above, withdrawal periods of 35 days for meat and offal in cattle, 53 days for meat and offal in horse and 24 hours for milk from cattle are justified.

IV. CLINICAL ASSESSMENT (EFFICACY)

As this is a generic application and bioequivalence with a reference product has been demonstrated, efficacy studies are not required. The efficacy claims for this product are equivalent to those of the reference product.

IV.A Pre-Clinical Studies

Since Prednisolon ad us. vet. 10 mg/kg solution for injection for cattle, horses, dogs and cats from Veyx is a generic application of the authorised reference product Prednisolon 1%, the applicant is not obliged to present own preclinical data, but can refer to the preclinical data from the reference product.

Prednisolon ad us. vet. 10mg/kg solution for injection from Veyx is, like the reference product, intended for intramuscular injection to cattle, horses, dogs and cats. Both products are considered bioequivalent, since the formulations are identical in terms of qualitative and quantitative composition and since the manufacturing process is the same. As stated by the applicant, a waiver from bioequivalence study requirements is, therefore, justified on the basis of chapter 7.1d of the bioequivalence guideline (EMA/CVMP/016/00-Rev.2).

Pharmacology

The active ingredient of Prednisolon ad us. vet. 10mg/ml suspension for injection from Veyx is prednisolone acetate. The pharmacological properties of the compound have been described in chapters 5.1, Pharmacodynamic properties, and 5.2,

Pharmacokinetic properties, of the product literature in line with the information given for the reference product.

Tolerance in the Target Species of Animals

In chapters 4.3, 4.5 and 4.10 of the product literature several contraindications, precautions and potential side effects of Prednisolon ad us. vet. 10mg/ml suspension for injection from Veyx at therapeutic doses and at overdoses are listed, which arise from the pharmacological properties of prednisolone in the target species. This information is in line with that given for the reference product, but has been updated with additional information on the safe and effective use of the product in line with other authorised prednisolone-containing products.

IV.B Clinical Studies

Prednisolon ad us. vet. 10mg/ml suspension for injection for cattle, horses, dogs and cats from Veyx is indicated for supportive treatment of the following conditions in horses, cattle, dogs and cats: acute non-infectious arthritis, bursitis, tenosynovitis and allergic skin disease, and in cattle: primary ketosis. Since the product from Veyx is a generic of the authorised reference product Prednisolon 1%, the applicant is not obliged to present own clinical data, but can refer to the preclinical data from the latter.

The clinical particulars of Prednisolon ad us. vet. 10mg/ml suspension for injection from Veyx have been described in the product literature in line with those for the reference product: Prednisolon ad us. vet. 10mg/ml suspension for injection from Veyx is for single intramuscular injection at doses from 0.2 – 0.5 mg/kg in large and of 0.5 – 1 mg/kg in small animals.

V . OVERALL CONCLUSION AND BENEFIT– RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics, the risk benefit profile for the target species is favourable and the quality and safety of the product for humans and the environment is acceptable.

MODULE 4

POST-AUTHORISATION ASSESSMENTS

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the Heads of Veterinary Medicinal Agencies website (www.hma.eu).

This section contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.

<None>